logo

DermNet NZ

  

Facts about the skin from DermNet New Zealand Trust. Topic index: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Acute generalised exanthematous pustulosis

What is acute generalised exanthematous pustulosis?

Acute generalised exanthematous pustulosis or AGEP is an uncommon skin eruption characterised by superficial pustules.

AGEP is usually classified as a severe cutaneous adverse reaction (SCAR) to a prescribed drug.

What are the clinical features of AGEP?

Typically the AGEP rash starts on the face or in the armpits and groin, and then becomes more widespread. It is characterised by the rapid appearance of areas of red skin studded with small sterile pustules (small blisters filled with white/yellow fluid). There tend to be more disease in skin folds. Facial swelling often arises.

AGEP may be associated with a fever and malaise, but generally the patient is not particularly unwell.

The rash may last for one to two weeks and then the skin peels off as it resolves.

Acute generalised exanthematous pustulosis (AGEP) Acute generalised exanthematous pustulosis (AGEP) Acute generalised exanthematous pustulosis (AGEP)
Acute generalised exanthematous pustulosis (AGEP) Acute generalised exanthematous pustulosis (AGEP) Acute generalised exanthematous pustulosis (AGEP)
Acute generalised exanthematous pustulosis (AGEP) Acute generalised exanthematous pustulosis (AGEP) Acute generalised exanthematous pustulosis (AGEP)
Acute generalised exanthematous pustulosis (AGEP)

Who gets AGEP?

AGEP has an estimated incidence of 3–5 cases per million population per year. It occurs in males and females, children and adults.

What causes AGEP?

Over 90% of cases of AGEP are provoked by medications, most often beta lactam antibiotics (penicillins, cephalosporins and quinolones). Other drugs that may cause AGEP include:

The onset of AGEP is usually within 2 days of exposure to the responsible medication.

Viral infections (Epstein-Barr virus, cytomegalovirus and others) and spider bites have also been implicated in some cases.

Recent research suggests that AGEP is associated with IL36RN gene mutations. These genetic abnormalities make the patient more susceptible to pustulosis when prescribed certain medications or when exposed to infection. Similar mutations are also found in some patients with other pustular disorders such as generalised pustular psoriasis, palmoplantar pustulosis and acrodermatitis continua of Hallopeau.

How is AGEP diagnosed?

AGEP is often diagnosed clinically. Supportive investigations may include:

How is AGEP treated?

New medicines should be discontinued following the onset of AGEP, particularly antibiotics.

Treatment is then based around relieving symptoms with moisturisers, topical corticosteroids, oral antihistamines and analgesics, until the rash resolves. Systemic therapy is rarely indicated.

Related information

References:

On DermNet NZ:

Other websites:

Books about skin diseases:

See the DermNet NZ bookstore

Author: Dr Diana Purvis, Dermatology Registrar, Green Lane Hospital, Auckland. Updated by Hon Assoc Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. September 2014.

DermNet NZ does not provide an online consultation service.
If you have any concerns with your skin or its treatment, see a dermatologist for advice.